The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Zoledronic Acid May Improve Bone Density in Elderly Women

Zoledronic Acid May Improve Bone Density in Elderly Women

June 15, 2015 • By Anne Harding (Reuters Health)

  • Tweet
  • Email
Print-Friendly Version / Save PDF

A single injection daily of zoledronic acid may improve bone mineral density (BMD) in frail elderly women in long-term care facilities, a new randomized controlled trial shows. However, the clinical importance of the improvement, observed over a two-year period, remains unclear, Dr. Neil M. Resnick, of the University of Pittsburgh, told Reuters Health in a telephone interview.

You Might Also Like
  • Women on Osteoporosis Drugs Still Need Bone Density Screenings
  • Taking Vitamin D Supplements May Not Improve Bone Health
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
Explore This Issue
June 2015

“It looks as if the results on the bone turnover are as good as they would be in a less frail, less advanced-age group, so that is all good news,” Dr. Resnick said. “What we don’t know now is whether or not that will translate to a reduction in fractures and their consequences.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Resnick and colleagues are now planning another trial to determine if the drug treatment does actually protect frail older women against fractures. “We were very pleased to see that it is safe, it is effective on the intermediate outcome, and that now sets the stage for the larger trial, which we now believe is justified,” he said.

Some 85% of elderly people living in institutions have osteoporosis, Dr. Resnick and his team note in an article online April 13 in JAMA Internal Medicine, and their risk of bone fractures is eight- to nine-fold higher than that of their community dwelling peers. But such individuals are usually not treated and not included in trials of osteoporosis medications, they add.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the Zoledronic acid in frail Elders to STrengthen bone (ZEST) study, 181 women 65 and older with osteoporosis living in nursing homes and assisted-living facilities received a 5-mg daily dose of zoledronic acid or placebo plus calcium and vitamin D supplementation. The researchers did not exclude participants with cognitive impairment, immobility, and multimorbidity.

Over two years, the researchers found, total hip BMD increased by an average of 3.9% in the women who received study medication, while total spine BMD increased by 3.6% (P<0.01 both). However, the zoledronic acid group had a higher rate of fractures than the placebo group (20% versus 16%), and a higher mortality rate (16% vs. 13%, OR 1.24).

While the percentage of patients who had a single fall during the study period was not significantly different between the two groups, 49% of the zoledronic acid group had multiple falls versus 35% of the placebo group. After adjusting for baseline frailty, this difference was no longer statistically significant. Much of the difference between the two groups was due to the fact that the zoledronic acid participants were frailer at baseline, on average, than the placebo group, Dr. Resnick said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Research Reviews Tagged With: bone density, outcome, Research, Women, zoledronic acidIssue: June 2015

You Might Also Like:
  • Women on Osteoporosis Drugs Still Need Bone Density Screenings
  • Taking Vitamin D Supplements May Not Improve Bone Health
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
  • Serum IGF-1 Tied to Fracture Risk in Elderly Women

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)